Hit Finding
Hit to Lead
Lead
Optimisation
Pre-clinical
Development
CMC
PARTNER
  • ELN 28 70% 70%
  • ELN 201 55% 55%
  • ELN 19 55% 55%
  • ELN 71 48% 48%
  • ROR1 Drug Conjugate 95% 95%
  • Bi-specific Drug Conjugate 75% 75%

Hit Finding

Hit to Lead

Lead

Optimisation

Pre-clinical

Development

CMC

PARTNER

  • ELN28 85% 85%
  • ELN 201 45% 45%
  • ELN src19 60% 60%
  • ELN sxc101 60% 60%
  • ROR1 Drug Conjugate 95% 95%
  • Bi-specific Drug Conjugate 60% 60%
  • Bi-specific Drug Conjugate 60% 60%